Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis

References

• McPherson T. Current understanding in pathogenesis of atopic dermatitis. Indian J Dermatol. 2016;61:649–655. doi:10.4103/0019-5154.19367427904184
   PubMed Web of Science ®Google Scholar
• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16. doi:10.1159/00037022025925336
   PubMed Web of Science ®Google Scholar
• Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28:1–13.
   Web of Science ®Google Scholar
• Maksimovic N, Jankovic S, Marinkovic J, Sekulovic LK, Zivkovic Z, Spiric VT. Health-related quality of life in patients with atopic dermatitis. J Dermatol. 2012;39:42–47. doi:10.1111/j.1346-8138.2011.01295.x22044078
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7:1–23. doi:10.1007/s13555-016-0170-1
   PubMed Web of Science ®Google Scholar
• Giavina-Bianchi M, Giavina-Bianchi P. Systemic treatment for severe atopic dermatitis. Arch Immunol Ther Exp (Warsz). 2019;67:69–78. doi:10.1007/s00005-018-0521-y30159581
   PubMed Web of Science ®Google Scholar
• Seegraber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11:467–474. doi:10.1080/17512433.2018.144964229557246
   PubMed Web of Science ®Google Scholar
• Frampton JE, Blair HA. Dupiluma: a review in moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2018;19:617–624. doi:10.1007/s40257-018-0370-930027349
   PubMed Web of Science ®Google Scholar
• Gadani SP, Cronk JK, Norris GT, Kipnis J. Interleukin-4: a cytokine to remember. J Immunol. 2012;189:4213–4219.23087426
   PubMed Web of Science ®Google Scholar
• Silverberg JK, Kantor R. The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017;35:327–334. doi:10.1016/j.det.2017.02.00528577802
   PubMed Web of Science ®Google Scholar
• McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015;75:38–50. doi:10.1016/j.cyto.2015.05.02326187331
   PubMed Web of Science ®Google Scholar
• Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2019;75:1–9.
   Web of Science ®Google Scholar
• Li R, Hadi S, Guttman-Yassky E. Current and emerging biologic and small molecule therapies for atopic dermatitis. Expert Opin Biol Ther. 2019;19(4):367–380.30672355
   PubMed Web of Science ®Google Scholar
• Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2:110. doi:10.4049/jimmunol.120224621994899
   PubMedGoogle Scholar
• Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–1494. doi:10.1056/NEJMra07408118385500
   PubMed Web of Science ®Google Scholar
• Bonness S, Bieber T. Molecular basis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007;7:382–386. doi:10.1097/ACI.0b013e3282a643c317873576
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther. 2013;13:549–561. doi:10.1517/14712598.2013.75870823323893
   PubMed Web of Science ®Google Scholar
• Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunol Res. 2011;50:87–96. doi:10.1007/s12026-011-8205-221442426
   PubMed Web of Science ®Google Scholar
• Dorsey NJ, Chapoval SP, Smith EP, Skupsky J, Scott DW, Keegan AD. STAT6 controls the number of regulatory T cells in vivo, thereby regulating allergic lung inflammation. J Immunol. 2013;191:1517–1528. doi:10.4049/jimmunol.130048623825312
   PubMed Web of Science ®Google Scholar
• Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J Mol Biol. 2013;425:1330–1339. doi:10.1016/j.jmb.2013.01.02423357170
   PubMed Web of Science ®Google Scholar
• Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126:332–337. doi:10.1016/j.clim.2007.11.00618166499
   PubMed Web of Science ®Google Scholar
• Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7–R12. doi:10.1016/j.jaci.2009.07.01219720210
   PubMed Web of Science ®Google Scholar
• Sehra S, Yaho Y, Howell MD, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol. 2010;184:3186–3190. doi:10.4049/jimmunol.090186020147633
   PubMed Web of Science ®Google Scholar
• Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295:459–464. doi:10.1007/s00403-004-0455-615014952
   PubMed Web of Science ®Google Scholar
• Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129:742–751. doi:10.1038/jid.2008.29518830273
   PubMed Web of Science ®Google Scholar
• Korenblat P, Kerwin E, Leshchenko I, et al. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids. Respir Med. 2018;134:143–149. doi:10.1016/j.rmed.2017.12.00629413502
   PubMed Web of Science ®Google Scholar
• Bujarski S, Parulekar AD, Hanania NA. Lebrikizumab in the treatment of asthma. Expert Opin Biol Ther. 2016;16:847–852. doi:10.1080/14712598.2016.118215227161908
   PubMed Web of Science ®Google Scholar
• Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, Placebo-controlled Phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863–871.e11.29353026
   PubMed Web of Science ®Google Scholar
• Dermira presents data from phase 2b study of lebrikizumab in patients with atopic dermatitis at fall clinical dermatology conference. Dermira, Inc.; 10 10, 2019 Available from: https://investor.dermira.com/news-releases/press-release-details/2019/Dermira-Presents-Data-From-Phase-2b-Study-of-Lebrikizumab-in-Patients-With-Atopic-Dermatitis-at-Fall-Clinical-Dermatology-Conference/default.aspx. Accessed 113, 2019.
   Google Scholar
• Evaluation of the efficacy and safety of lebrikizumab in moderate to severe atopic dermatitis (ADvocate1). ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT04146363?term=lebrikizumab&phase=2&draw=2&rank=4. Accessed 1120, 2019.
   Google Scholar
• Akinlade B, Guttman-Yassky E, de Bruin-weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181:459–473. doi:10.1111/bjd.1786930851191
   PubMed Web of Science ®Google Scholar
• Henriksson JT, Coursey TG, Corry DB, De Paiva CS, Pflugfelder SC. IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells. Invest Ophthalmol Vis Sci. 2015;56:4187–4197.
   Web of Science ®Google Scholar
• Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-tot-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748–756. doi:10.1136/thoraxjnl-2014-20671926001563
   PubMed Web of Science ®Google Scholar
• Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR. Interleukin-13 in asthma and other eosinophilic disorders. Front Med (Lausanne). 2017;4:139. doi:10.3389/fmed.2017.0013929034234
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–1098. doi:10.1056/NEJMoa110646921812663
   PubMed Web of Science ®Google Scholar
• Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomized, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4:781–796. doi:10.1016/S2213-2600(16)30265-X27616196
   PubMed Web of Science ®Google Scholar
• Faiz S, Giovannelli J, Celine Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life FRe ch multicenter adult cohort. J Am Acad Dermatol. 2019;81:143–151. doi:10.1016/j.jaad.2019.02.05330825533
   PubMed Web of Science ®Google Scholar
• Lee DE, Clark AK, Tran KA, Shi VY. New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatolog Treat. 2018;29:364–374. doi:10.1080/09546634.2017.137373628853956
   PubMed Web of Science ®Google Scholar
• Garcia-Posada L, Hodges RR, Diebold Y, Dartt DA. Context-dependent regulation of conjunctival goblet cell unction by allergic mediators. Sci Rep. 2018;8:12162. doi:10.1038/s41598-018-30002-x30111832
   PubMed Web of Science ®Google Scholar